TP-317: A new pro-resolving approach for treatment of inflammatory bowel diseases

TP-317 is a novel SPM-based drug that is being developed for the treatment of an orphan disease within IBD. The active agent in TP-317 has been shown in preclinical studies to have potent inflammation resolving effects in colitis. These data suggest multiple mechanisms of action including inhibition of pro-inflammatory signals, reduced penetration of bacteria into the intestinal wall, and promotion of tissue repair and healing.